NASDAQ · RNXT
RenovoRx, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for RNXT: Nov 05, 2026
RenovoRx, Inc. Common Stock is expected to report earnings on 11/05/2026 after market close. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.05. The reported EPS for the same quarter last year was $-0.08.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.05 | $-0.03 | $-0.07 | 2 |
| Dec 2026 | $-0.05 | $-0.03 | $-0.07 | 2 |
| Mar 2027 | $-0.05 | $-0.03 | $-0.07 | 2 |
| Jun 2027 | $-0.04 | $-0.02 | $-0.06 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · MarketBeat · The Motley Fool- RTTNews · Oct 8, 5:29 AM EDTRenovoRx Enrolls First Patient In UVM-Sponsored Pancreatic Cancer PRISM-TAMP Trial(RTTNews) – RenovoRx, Inc. (RNXT), a life sciences company developing oncology therapies, has enrolled its first patient in PRISM-TAMP, "PDAC Regression and Intraoperative Surgical Margin With Neoadjuvant TAMP," an investigator-initiated trial (IIT) sponsored by the University of
- RTTNews · Sep 2, 11:20 PM EDT6 Biotech Stocks To Watch Ahead Of Key Catalysts: RenovoRx, Eupraxia, Connect Bio, Kardigan & More(RTTNews) – Today, we bring you a list of six stocks to watch in the coming days and months. Each company has potentially market-moving catalysts on the horizon, ranging from clinical data readouts and investor conference presentations to key FDA decisions. These binary events ca
- RTTNews · Sep 1, 3:46 AM EDTBiotech Stocks At 52-Week Highs – RNXT +15%, EOLS, CRNX, APGE(RTTNews) – The following biotech stocks reached a 52-week high on August 31, 2026, driven by achieving new regulatory milestones or an upcoming acquisition.
- RTTNews · Aug 31, 5:01 AM EDTBiotech Stocks At 52-Week Highs – RNXT +12%, BLSM, RVTY, ATRC, BFRI(RTTNews) – The following biotech stocks reached a 52-week high on August 28, 2026, as various clinical trials reported initial data and companies reached certain regulatory milestones.
- RTTNews · Aug 28, 10:42 AM EDTWeekly Buzz: GILD, ROIV Win FDA Nod; BHVN, LLY Strike Deal; SYRE Misses Monotherapy Goal(RTTNews) – This week's biotech landscape saw a wave of regulatory approvals across HIV, rare diseases, immunology, and diagnostics, alongside strategic licensing deals, manufacturing collaborations, and mixed clinical trial readouts.
- RTTNews · Aug 26, 3:02 AM EDTRenovoRx Publishes Positive PK/PD Data For RenovoCath In Drug Delivery To Tumors; Stock Up(RTTNews) – RenovoRx Inc. (RNXT), a life sciences company, on Tuesday reported the publication of pharmacokinetic and pharmacodynamic data from the Phase 3 TIGeR-PaC trial for RenovoCath, a patented drug delivery system. The results were released in the journal of Cancer Chemothe
- BNK Invest · Aug 25, 1:52 PM EDTTuesday Sector Leaders: Metals & Mining, Biotechnology StocksIn trading on Tuesday, metals & mining shares were relative leaders, up on the day by about 2.8%. Leading the group were shares of Critical Metals, up about 19.7% and shares of 5E Advanced Materials up about 9.3% on the day. Also showing relative strength are biotechnology
- RTTNews · Aug 21, 9:12 AM EDTRenovoRx Regains Nasdaq Compliance As Shares Maintain $1 Minimum Bid(RTTNews) – RenovoRx (RNXT) has regained compliance with Nasdaq's minimum bid price requirement for continued listing on the Nasdaq Capital Market.
- MarketBeat · Aug 16, 9:01 PM EDTRenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 CentersRenovoRx (NASDAQ:RNXT) executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company’s Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar h
- MarketBeat · Aug 12, 10:04 PM EDTRenovoRx Q2 Earnings Call HighlightsRenovoRx (NASDAQ:RNXT) reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer. For the quarter ended June 30, 2026, the company generated revenue of $909,000, up approxim
- The Motley Fool · Aug 12, 8:28 PM EDTRenovoRx (RNXT) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 12, 6:15 PM EDTRenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue EstimatesRenovoRx (RNXT) delivered earnings and revenue surprises of +37.50% and +25.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for RenovoRx, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.